Thank you, Manny, and good morning, everyone. I share Manny's enthusiasm for Mistras' immediate outlook and longer-range future. Our focus on transformative discipline will allow us to leverage our footprint and coupled with our new commercial focus will lead to improved results and profitable growth. First quarter results continue to demonstrate our commitment to unlocking significant value through the ongoing implementation of Project Phoenix. While we have already made significant progress, there is more work to do as we plan to achieve our target of an incremental SG&A reduction of $12 million in 2024 versus the prior year. This will not only generate an improved bottom line return, but will also provide funds to reinvest in our high-margin growth initiatives such as Data Analytical Solutions and the Aerospace and Defense industry. This is an exciting time for Mistras and the entire organization is focused on capitalizing on the unique growth opportunities in our markets. And our first quarter performance demonstrated this with a great start to what we anticipate will be one of our all-time high adjusted EBITDA performance shares in 2024. For the second consecutive quarter, we exceeded financial expectations while making significant organizational progress. The first quarter marked the second consecutive quarter where we generated significant organic revenue growth, actually increasing from 8.2% in the fourth quarter of last year to 9.8% this quarter. As Manny noted, we were up in our 2 largest end markets, in part due to contributions from our improved commercial focus, which has provided a benefit from the successful implementation of strategic price increases. The Oil & Gas industry was up nearly 15% on a strong spring turnaround season. Although turnaround activity remained robust as stated last quarter, we are anticipating this sector's growth to level out in the second half of the year due to a more moderate fall turnaround season compared to the robust spring turnaround, which continued into April 2024. Aerospace and Defense continued its expansion, continuing its bounce back from the fourth quarter with another quarter of solid growth, up nearly 19%. Our North American Aerospace and Defense business has recovered to pre-pandemic levels in the first quarter of 2024. The Aerospace and Defense market remains robust and was once again led by the strong performance in our West Penn business. For the third consecutive quarter, they had record results primarily as a result of the continued ramp-up of our new Georgia facility, as well as increased demand for our services, which are helping to debottleneck the industry supply chain. The International Aerospace business revenues were also up significantly in the quarter. Private space was also strong in the first quarter, and we expect this business to hold up well over the immediate term as the pace of space launches has not let up. As one of our primary growth initiatives, we are investing in our Aerospace and Defense business to accelerate growth. So we expect strong results from the Aerospace and Defense segment throughout the year. As Manny noted, Data Analytical Solutions had a slower start than anticipated due to project delays and implementation pushouts. However, we saw momentum build later in the quarter, which we believe will lead to continued growth during the second quarter and remainder of the year. Again, this is a focused growth area and we are investing in our capabilities by adding highly skilled data analysts and expanding our predictive solutions. Both gross profit and margin were up in the first quarter despite the slow start for Data Analytical Solutions, driven by overall revenue growth, the cost reduction benefit from Project Phoenix, and the previously mentioned positive pricing actions. This was somewhat offset by higher health care claims expense -- experience in the quarter. Selling, general and administrative expenses were down $1.6 million or nearly 4% from a year ago, primarily reflecting the effect of Project Phoenix on headcount. We remain committed to our goal of reducing SG&A to approximately 21% of full year 2024 revenue with $12 million of expected savings being the product of Project Phoenix. As we have mentioned, we are still working our way through a full implementation. For the quarter, we reported GAAP net income of $1 million or $0.03 per share. Excluding reorganization and other nonrecurring costs, net of tax, non-GAAP net income was $2.2 million or $0.07 per share for the quarter. Adjusted EBITDA was up 55% to $16.2 million, which was our best ever first quarter adjusted EBITDA performance. This follows the record fourth quarter adjusted EBITDA reported just last quarter. As a result of an increase in working capital and incremental strategic capital expenditures, we generated negative free cash flow in first quarter, which is not unusual for the first quarter of the year. As it relates to 2024, this negative cash flow was related to an increase in working capital related to timing of customer invoicing, which we are intently focused on improving in the second quarter and remainder of 2024. We still believe that we will generate at least $34 million in free cash flow for the year despite an increase in growth capital expenditures. Interest expense was $4.4 million for the quarter, increasing by $0.3 million from the prior year due to the higher interest rate environment and an increase in the average debt balance outstanding. Our trailing 12-month bank defined leverage ratio was 3.06x as of March 31, 2024, which is the lowest this ratio has been since the third quarter of [ 2028 ]. Based on our current 2024 projections, we expect to be able to achieve a targeted 3x or lower ratio by midyear, primarily due to the anticipated increase in our trailing 12-month EBITDA, even if only a modest reduction in outstanding debt. We have articulated a strategy and continue to emphasize debt reduction as our primary use of free cash flow. However, based on current financial projections, we believe investments in capital expenditures and other resources that support our organic growth strategy, while providing superior returns also represent an excellent use of free cash flow. Longer term, we believe a 2.5x leverage ratio is achievable. And at that point, we would gain additional optionality as it relates to free cash flows. Actually, we believe a 2.5x leverage ratio can be achieved by the end of '24 and maintained over the longer term. So we will be balancing these 2 priorities to maximize shareholder value. While these are still early days, our results have been very encouraging, and we are confident in our outlook, but there is more work to be done and additional objectives to be achieved. 2024 is shaping up to be both a transformative and record year. Most importantly, we expect to set a new foundation on which to grow profitably, given our new commercial focus and its ability to drive profitable growth. We sincerely appreciate your continued support and expect to reward your patients with significantly improved results in 2024. At this time, I would like to turn the call back over to Manny for his closing remarks before we move on to take your questions.